Ianniello et al. demonstrated that upregulated METTL3/METTL14 could drive the malignant proliferation of CML cells and mediate the resistance against TKIs [122]. The gene discussed is METTL14; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.